CYP19A1 and breast cancer: About 80% of breast cancer tissues highly express estrogen receptor (ER), and Naringin plays an anti estrogen and anti aromatase activity role by regulating estrogen signal transduction and aromatase inhibition (El-Kersh et al., 2021), thereby inhibiting the proliferation of breast cancer cells.